PTCL Gene Expression Profiling for Accurate Subtype Diagnosis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic methods for peripheral T-cell lymphoma (PTCL) are inadequate, leading to challenges in accurately classifying subtypes and selecting appropriate treatments, with 30-50% of cases being unclassifiable and patients having a poor prognosis despite standard-of-care therapies.

Innovation Solution

A method involving gene expression profiling using specific biomarkers to differentiate PTCL subtypes, including AITL, ALK−ALCL, ATLL, ENKTL, ALK+ALCL, and PTCL-NOS, through nucleic acid isolation and analysis of gene signatures, coupled with subtype-specific treatments.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If current immunophenotypic and molecular markers are used for PTCL diagnosis, then the diagnostic process is simple, but 30-50% of cases remain unclassifiable and diagnosis accuracy is low

Engineering Contradiction:

Improvediagnosis accuracyVSAvoiddiagnostic method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent transitions from traditional immunophenotypic markers to gene expression parameters, fundamentally changing the diagnostic parameters used. By measuring expression levels of specific genes (such as BCL6, MAD2L2, CD3E, CD4, CD8A) instead of relying on conventional markers, the method achieves superior classification accuracy for PTCL subtypes, resolving the limitation of current markers that leave 30-50% of cases unclassifiable

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The gene expression profiling method serves multiple diagnostic functions simultaneously: it classifies PTCL subtypes, identifies unclassifiable cases, and provides prognostic information. This multi-functional approach replaces multiple separate diagnostic procedures with a single comprehensive test, improving both accuracy and efficiency while managing complexity through integration

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If subtype-specific treatments are implemented, then treatment efficacy improves, but treatment selection complexity increases

Engineering Contradiction:

Improvetreatment efficacyVSAvoidtreatment selection complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs preliminary classification of PTCL subtypes through gene expression profiling before treatment selection. By determining the specific subtype (e.g., AITL, ALK-ALCL, ATLL, ENKTL, ALK+ALCL, or PTCL-NOS) in advance, the method guides clinicians to select appropriate subtype-specific therapies, thereby improving treatment efficacy while structuring the decision-making process to manage complexity

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent segments PTCL into distinct molecular subtypes based on gene expression profiles, allowing for targeted treatment approaches for each segment. This segmentation enables clinicians to match specific therapies to specific subtype segments rather than using uniform treatment protocols, improving reliability of treatment outcomes while organizing the complexity through systematic categorization

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250283177A1Biomarkers and methods of use thereof for treatment of peripheral t-cell lymphoma

Publication Date: 2025.09.11 BOARD OF RGT UNIV OF NEBRASKA

AI summary

The present disclosure is directed to methods of genetically subtypin peripheral t-cell lymphoma.